Short Interest in Briacell Therap (NASDAQ:BCTX) Grows By 84.6%

Briacell Therap (NASDAQ:BCTX) was the recipient of a significant increase in short interest during the month of May. As of May 29th, there was short interest totaling 867,761 shares, an increase of 84.6% from the May 14th total of 470,162 shares. Based on an average daily trading volume, of 269,245 shares, the days-to-cover ratio is currently 3.2 days. Currently, 10.0% of the company’s stock are short sold.

Institutional Trading of Briacell Therap

A hedge fund recently bought a new stake in Briacell Therap stock. Citadel Advisors LLC purchased a new position in Briacell Therap (NASDAQ:BCTX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned 1.63% of Briacell Therap at the end of the most recent quarter. 15.42% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on BCTX shares. Weiss Ratings restated a “sell (e+)” rating on shares of Briacell Therap in a report on Monday, April 20th. Wall Street Zen raised Briacell Therap from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Briacell Therap Trading Up 4.0%

BCTX stock traded up $0.11 during trading on Tuesday, reaching $2.85. The stock had a trading volume of 96,701 shares, compared to its average volume of 366,479. The firm has a market cap of $24.80 million, a PE ratio of -0.12 and a beta of 1.21. The stock’s 50 day moving average is $3.79 and its two-hundred day moving average is $5.26. Briacell Therap has a 52 week low of $2.60 and a 52 week high of $32.10.

Briacell Therap (NASDAQ:BCTX) last released its quarterly earnings results on Tuesday, June 9th. The company reported ($0.99) earnings per share (EPS) for the quarter.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.